Last reviewed · How we verify
NCT03581500
Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer
Phase 2 trial testing Hyperpolarized Carbon C 13 Pyruvate in Prostate Adenocarcinoma. Withdrawn.
16 October 2024
Quick facts
| Lead sponsor | M.D. Anderson Cancer Center |
|---|---|
| Phase | Phase 2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Start date | 6 February 2019 |
| Primary completion | 16 October 2024 |
| Estimated completion | 16 October 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Hyperpolarized Carbon C 13 Pyruvate — full drug profile →
- Magnetic Resonance Spectroscopic Imaging
Conditions studied
- Prostate Adenocarcinoma — all drugs for Prostate Adenocarcinoma →
- PSA Level Greater Than Ten — all drugs for PSA Level Greater Than Ten →
- Stage IIB Prostate Cancer AJCC v8 — all drugs for Stage IIB Prostate Cancer AJCC v8 →
- Stage III Prostate Cancer AJCC v8 — all drugs for Stage III Prostate Cancer AJCC v8 →
Sponsor
M.D. Anderson Cancer Center — full company profile →
Who can join
Eligibility, male only, with Prostate Adenocarcinoma or PSA Level Greater Than Ten. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase II trial studies how well hyperpolarized carbon C 13 pyruvate magnetic resonance spectroscopic imaging works in predicting treatment response in patients with prostate cancer. Hyperpolarized carbon C 13 pyruvate magnetic resonance spectroscopic imaging may help to accurately predict how prostate cancer patients will respond to standard therapy (abiraterone and apalutamide).
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Comprehensive Literature Review of Hyperpolarized Carbon-13 MRI: The Road to Clinical Application.
Vaeggemose M, F Schulte R, Laustsen C. · · 2021 · cited 35× · PMID 33916803 · DOI 10.3390/metabo11040219 -
Metabolic response to radiation therapy in cancer.
Read GH, Bailleul J, Vlashi E, Kesarwala AH. · · 2022 · cited 25× · PMID 34961986 · DOI 10.1002/mc.23379 -
Lactate as Key Metabolite in Prostate Cancer Progression: What Are the Clinical Implications?
Chetta P, Sriram R, Zadra G. · · 2023 · cited 22× · PMID 37444583 · DOI 10.3390/cancers15133473
Verify or expand the search:
- PubMed search for NCT03581500
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Hyperpolarized Carbon C 13 Pyruvate
Trials testing the same drug.
- NCT04565327 — Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal Adenocarcinoma · Phase 2 · terminated
- NCT04589624 — An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies · Phase 1 · recruiting
- NCT04286386 — Development and Evaluation of a Quantitative HP MRI for Clinical Prostate Cancer Exam · active not recruiting
- NCT03830151 — Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors · Phase 1 · recruiting
- NCT04258462 — Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors · Phase 2 · active not recruiting
Other recruiting trials for Prostate Adenocarcinoma
Currently open trials in the same condition.
- NCT06831032 — Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response · NA · recruiting
- NCT07285057 — Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance · Phase 2 · recruiting
- NCT06957691 — Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Pro · Phase 2 · recruiting
- NCT07025369 — Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With H · Phase 2 · recruiting
- NCT06967961 — Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers · NA · recruiting
Other M.D. Anderson Cancer Center trials
Trials by the same sponsor.
- NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
- NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
- NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
- NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
- NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03581500 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
- Last refreshed: 23 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03581500.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing